Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.48 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.47 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407927 | 1.00 | DGAT1 (0.72) | DGAT1CYP11B1CYP11B2ALDH1A1SOAT2 | |
| SCHEMBL13190130 | 0.88 | CYP11B1 (0.61) | DGAT1CYP11B1CYP11B2ALDH1A1KDM1A | |
| SCHEMBL410377 | 0.86 | DGAT1 (0.74) | DGAT1ALDH1A1SOAT2KDM1AKDM1B | |
| SCHEMBL410378 | 0.86 | DGAT1 (0.74) | DGAT1ALDH1A1SOAT2KDM1AKDM1B | |
| SCHEMBL410152 | 0.86 | DGAT1 (0.77) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL410151 | 0.86 | DGAT1 (0.77) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197146 | 0.83 | DGAT1 (1.00) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197542 | 0.83 | DGAT1 (1.00) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197151 | 0.83 | DGAT1 (0.69) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10260835 | 0.83 | DGAT1 (0.69) | DGAT1SOAT2CYP2C9SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2408744-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885CYP11B1 721/4885CYP11B2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.